Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,737,765 Shares of Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,737,765 shares of the company’s stock in a transaction on Monday, December 15th. The stock was bought at an average price of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the purchase, the director directly owned 24,826,344 shares in the company, valued at approximately $28,302,032.16. This represents a 7.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Gregg Williams also recently made the following trade(s):

• On Saturday, November 15th, Gregg Williams purchased 1,737,764 shares of Vivani Medical stock. The shares were bought at an average cost of $1.14 per share, with a total value of $1,981,050.96.
• On Monday, October 27th, Gregg Williams purchased 3,703,703 shares of Vivani Medical stock. The stock was purchased at an average price of $1.62 per share, with a total value of $5,999,998.86.
• On Wednesday, October 15th, Gregg Williams acquired 1,737,764 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.14 per share, for a total transaction of $1,981,050.96.

Vivani Medical Stock Up 4.4%

VANI opened at $1.41 on Wednesday. The stock’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.37. The company has a market capitalization of $102.86 million, a P/E ratio of -3.13 and a beta of 3.24. Vivani Medical, Inc. has a 52 week low of $0.91 and a 52 week high of $1.92.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. Equities analysts anticipate that Vivani Medical, Inc. will post -0.41 earnings per share for the current year.

Institutional Trading of Vivani Medical

A number of institutional investors have recently modified their holdings of the company. Connective Capital Management LLC grew its holdings in Vivani Medical by 796.2% in the first quarter. Connective Capital Management LLC now owns 162,098 shares of the company’s stock worth $170,000 after purchasing an additional 144,010 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Vivani Medical in the 2nd quarter worth $25,000. Citadel Advisors LLC purchased a new position in Vivani Medical during the 3rd quarter worth $26,000. Finally, Susquehanna International Group LLP increased its position in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after buying an additional 16,200 shares in the last quarter. 6.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on VANI shares. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Vivani Medical in a research report on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Tuesday, October 14th. Finally, Zacks Research raised shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Vivani Medical has a consensus rating of “Hold” and an average price target of $4.00.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.